EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSSTUG00000021257
Gene Symbol: GABRB2
3 Cross references
186 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSSTUG00000010837
Gene Symbol: GABRB2
3 Cross references
185 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSSTUG00000016691
Gene Symbol: GABRB3
3 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSSTUG00000047073
Gene Symbol: GABRB3
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSSTUG00000039592
Gene Symbol: GABRB3
3 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSSTUG00000048620
Gene Symbol: GABRD
3 Cross references
186 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSSTUG00000043371
Gene Symbol: GABRD
3 Cross references
187 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSSTUG00000036072
Gene Symbol: GABRG1
3 Cross references
185 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSSTUG00000031505
Gene Symbol: GABRG1
1 Cross references
182 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSSTUG00000019385
Gene Symbol: GABRG2
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSSTUG00000009879
Gene Symbol: GABRG2
3 Cross references
199 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSSTUG00000016625
Gene Symbol: GABRG3
3 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).